FREE Case Review (866) 588-0600

Viekira Pak FAQ

The hepatitis C treatment Viekira Pak has been linked to an increased risk for serious liver disease which could require a liver transplant or even cause death, according to an FDA warning.

Free Confidential Lawsuit Evaluation: If you had liver failure or required a liver transplant, or someone you know died after taking Viekira Pak, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

What is Viekira Pak?

Viekira Pak is a hepatitis C treatment that contains the antiviral medications ombitasvir, paritaprevir, ritonavir, and dasabuvir. These drugs work by preventing hepatitis C virus (HCV) from multiplying in the body. Viekira Pak is approved to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.

What is the Dosing?

The recommended oral dose of Viekira Pak is 2 ombitasvir/paritaprevir/ritonavir 12.5/75/50 mg tablets once daily (in the morning) and 1 dasabuvir 250 mg tablet twice daily (morning and evening) at mealtime.

What’s the Problem with Viekira Pak?

Viekira Pak may cause severe liver problems, especially in people with certain types of cirrhosis. These severe liver problems can lead to the need for a liver transplant, or can lead to death.

Which Side Effects has Viekira Pak Been Linked to?

  • Liver disease
  • Liver failure
  • Hepatic decompensation
  • Hepatic failure
  • Allergic reactions
  • Rash
  • Anemia
  • Thinning blood
  • Tiredness
  • Weakness
  • Nausea
  • Dizziness
  • Itching
  • Difficulty sleeping

What Should I Tell My Doctor Before Taking Viekira Pak?

Tell your doctor if you:

  • Have liver problems other than hep C infection, HIV infection, or any other medical conditions.
  • Had a liver transplant.
  • Take any of the following medications: tacrolimus (Prograf) or cyclosporine (Gengraf, Neoral, Sandimmune).
  • If you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.

Which Injuries is your Law Firm Accepting?

Our lawyers are accepting potential lawsuits on behalf of people who had liver failure or required a liver transplant, or died from liver disease after taking Viekira Pak.

Is There a Class Action?

No class action lawsuit has yet been filed in the Viekira Pak litigation. However, if multiple lawsuits are filed alleging similar injuries, these complaints may be consolidated into a multidistrict litigation (MDL) for pretrial handling. MDLs are different from class actions, and it is generally agreed that consolidating cases instead of proceeding in a class action is a more efficient way of handling claims arising from injuries associated with pharmaceutical products.

Have There Been Any Settlements?

The first Viekira Pak lawsuits were only recently filed, and the proceedings are still in their early stages. It will likely be several years before AbbVie considers settling some or all of the cases. However, our lawyers feel that the manufacturer will eventually be required to pay substantial compensation as a result of their decision to place profits ahead of safety when they withheld information about the potential health risks of Viekira Pak.

Do I Have a Viekira Pak Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Viekira Pak lawsuits. We are handling individual litigation nationwide and currently accepting new liver disease cases in all 50 states.

Free Case Evaluation: Again, if you had liver failure or required a liver transplant, or someone you know died from liver failure after taking Viekira Pak, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
*
*
*
Awards & recognition